 |
市場調査レポート
商品コード
1423400
アルブミン市場レポート：製品、用途、エンドユーザー、地域別、2024年～2032年Albumin Market Report by Product, Application, End User, and Region 2024-2032 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| アルブミン市場レポート：製品、用途、エンドユーザー、地域別、2024年～2032年 |
|
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
世界のアルブミン市場規模は2023年に61億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに98億米ドルに達し、2024年から2032年の間に5.4%の成長率（CAGR）を示すと予測しています。低血球血症を治療するための手術で製品が広く採用されていること、特に新興国市場全体でヘルスケアインフラが改善されていること、ヘルスケアへの民間投資と公共投資の両方が流入していることが、市場を推進している主な要因の一部です。
アルブミンは主に肝臓で生成されるタンパク質で、様々な生理機能において重要な役割を果たしています。ヒトの血漿中に最も多く含まれるタンパク質であり、浸透圧を維持することで血液量を調節する役割を果たしています。アルブミンはまた、ホルモン、脂肪酸、薬物などの物質のキャリアー分子としても働き、全身への輸送を助けています。アルブミンの重要な働きは、血管からの体液漏れを防ぎ、必要な体液が循環系内に留まるようにすることです。血液中のアルブミン濃度が異常に高い場合、様々な健康状態が示唆されます。低レベルの場合は、肝臓や腎臓の障害、栄養失調、慢性疾患を示唆する可能性があり、高レベルの場合は、一般的にあまり見られず、脱水や重度の感染症を示唆する可能性があります。そのため、アルブミン値の測定は、日常的な医学的評価の一環として血液検査に含まれることが多いです。
外科手術の増加が世界市場を牽引しています。アルブミンは、血漿量が減少した状態である血液量減少症を治療するための手術で一般的に使用されます。世界人口の高齢化が進み、手術技術が進歩し続けるにつれて、実施される手術の数は増加しています。この動向はアルブミン需要の増加に直結するため、市場成長の原動力となっています。市場成長に寄与するもう一つの重要な要因は、アルブミン業界の新興市場への進出です。新興国市場は、医療支出の増加とヘルスケア・インフラの改善により、未開拓の市場となっています。これらの国々のヘルスケアシステムが進歩するにつれて、アルブミンを含む高品質の医療用品に対する需要が高まる。加えて、アルブミンを必要とする疾患の早期診断・早期治療の重要性に対する認識が加速していることも、市場を牽引する要因となっています。さらに、ヘルスケアへの民間および公的投資の流入は、市場の前向きな見通しを生み出しています。
アルブミン市場の動向と促進要因：
慢性疾患の発生率の上昇
アルブミン業界にとって最も重要な市場促進要因の一つは、肝硬変、腎障害、糖尿病などの慢性疾患の発生率の上昇です。これらの疾患はしばしばアルブミンレベルの異常を引き起こすため、定期的なモニタリングと可能なサプリメントが必要となります。加えて、これらの慢性疾患の有病率の上昇は、人口の高齢化、食生活の乱れ、運動不足やストレスレベルの高さなどのライフスタイル要因に関連しています。このような背景から、患者数の増加に伴い、診断と治療の両方の目的でアルブミン製品の供給が増加しています。このような疾患の治療におけるアルブミンへのニーズの高まりが、業界の成長を後押ししています。病院や診療所は、アルブミンベースの検査や治療への依存を強めており、それによって需要が増加し、市場の成長を促進しています。
バイオテクノロジーと医薬品研究の進歩
バイオテクノロジーと製薬研究における技術的進歩もまた、アルブミン業界の主要な推進力であることが証明されています。これらの進歩は、アルブミンの単離、精製、大規模生産の方法の改善を促進し、それによってアルブミンをより入手しやすく、コスト効率の良いものにしています。さらに、組換えDNA技術における革新的な技術は、標的治療のためのドラッグデリバリー剤としての使用など、アルブミン応用の新たな道を開いた。さらに、研究の進歩は、創傷治癒や組織再生といった新しい用途におけるアルブミンの使用に道を開いた。研究開発活動への継続的な投資は、アルブミン業界の有望な軌道を示し、その拡大に寄与しています。
規制支援と承認
政府の規制とガイドラインは、アルブミン市場を推進する上で重要な役割を果たしています。規制機関は、アルブミン製品の安全な生産、品質管理、流通のためのガイドラインを提供しています。これと関連して、このような標準化の存在は、消費者の信頼を構築するだけでなく、製薬会社が高品質の製品に投資することも奨励しています。アルブミンベースの新製品や治療法のタイムリーな承認は、市場浸透を大幅に加速させ、業界の促進要因として機能します。さらに、これらのガイドラインの世界の調和は、合理的かつ効率的なサプライチェーンを保証し、革新的なアルブミンベースの新製品の市場投入までの時間を短縮します。
本レポートで扱う主な質問
- 2023年の世界アルブミン市場規模は？
- 2024-2032年のアルブミン世界市場の予想成長率は？
- 世界のアルブミン市場を牽引する主要因は何か？
- COVID-19の世界アルブミン市場への影響は？
- アルブミン世界市場の製品別区分は？
- アルブミン世界市場の用途別区分は？
- 世界のアルブミン市場のエンドユーザー別区分は？
- アルブミン世界市場の主要地域は？
- アルブミン世界市場の主要プレイヤー/企業は？
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査目的
- 利害関係者
- データソース
- 一次情報
- 二次情報
- 市場推定
- ボトムアップアプローチ
- トップダウンアプローチ
- 調査手法
第3章 エグゼクティブサマリー
第4章 イントロダクション
- 概要
- 主要産業動向
第5章 アルブミンの世界市場
- 市場概要
- 市場実績
- COVID-19の影響
- 市場予測
第6章 市場内訳：製品別
- ヒト血清アルブミン
- 市場動向
- 市場予測
- 牛血清アルブミン
- 市場動向
- 市場予測
- 遺伝子組換えアルブミン
- 市場動向
- 市場予測
第7章 市場内訳：用途別
- 治療薬
- 市場動向
- 市場予測
- 製剤・ワクチン
- 市場動向
- 市場予測
- メディア成分
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第8章 市場内訳：エンドユーザー別
- 病院・クリニック
- 市場動向
- 市場予測
- 製薬・バイオ企業
- 市場動向
- 市場予測
- 研究機関
- 市場動向
- 市場予測
第9章 市場内訳：地域別
- 北米
- 米国
- 市場動向
- 市場予測
- カナダ
- 市場動向
- 市場予測
- 米国
- アジア太平洋
- 中国
- 市場動向
- 市場予測
- 日本
- 市場動向
- 市場予測
- インド
- 市場動向
- 市場予測
- 韓国
- 市場動向
- 市場予測
- オーストラリア
- 市場動向
- 市場予測
- インドネシア
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
- 中国
- 欧州
- ドイツ
- 市場動向
- 市場予測
- フランス
- 市場動向
- 市場予測
- 英国
- 市場動向
- 市場予測
- イタリア
- 市場動向
- 市場予測
- スペイン
- 市場動向
- 市場予測
- ロシア
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
- ドイツ
- ラテンアメリカ
- ブラジル
- 市場動向
- 市場予測
- メキシコ
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
- ブラジル
- 中東・アフリカ地域
- 市場動向
- 市場内訳：国別
- 市場予測
第10章 SWOT分析
- 概要
- 強み
- 弱み
- 機会
- 脅威
第11章 バリューチェーン分析
第12章 ポーターのファイブフォース分析
- 概要
- 買い手の交渉力
- 供給企業の交渉力
- 競合の程度
- 新規参入業者の脅威
- 代替品の脅威
第13章 価格分析
第14章 競合情勢
- 市場構造
- 主要企業
- 主要企業のプロファイル
- Albumedix Ltd
- Biotest AG
- Celgene Corporation（Bristol-Myers Squibb Company）
- CSL Limited
- Grifols SA
- HiMedia Laboratories
- Medxbio Pte Ltd
- Merck KGaA
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc.
- Ventria Bioscience Inc.
List of Figures
- Figure 1: Global: Albumin Market: Major Drivers and Challenges
- Figure 2: Global: Albumin Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Albumin Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Albumin Market: Breakup by Product (in %), 2023
- Figure 5: Global: Albumin Market: Breakup by Application (in %), 2023
- Figure 6: Global: Albumin Market: Breakup by End User (in %), 2023
- Figure 7: Global: Albumin Market: Breakup by Region (in %), 2023
- Figure 8: Global: Albumin (Human Serum Albumin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 9: Global: Albumin (Human Serum Albumin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 10: Global: Albumin (Bovine Serum Albumin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: Albumin (Bovine Serum Albumin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: Albumin (Recombinant Albumin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: Albumin (Recombinant Albumin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: Albumin (Therapeutics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: Albumin (Therapeutics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: Albumin (Drug Formulation and Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: Albumin (Drug Formulation and Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: Albumin (Component of Media) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: Albumin (Component of Media) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: Albumin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: Albumin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: Albumin (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: Albumin (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: Global: Albumin (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: Global: Albumin (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: Global: Albumin (Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: Global: Albumin (Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: North America: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: North America: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: United States: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: United States: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: Canada: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: Canada: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: Asia-Pacific: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: Asia-Pacific: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: China: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: China: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: Japan: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: Japan: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: India: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: India: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: South Korea: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: South Korea: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: Australia: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: Australia: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: Indonesia: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: Indonesia: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: Others: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: Others: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: Europe: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: Europe: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: Germany: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: Germany: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: France: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: France: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: United Kingdom: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: United Kingdom: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: Italy: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: Italy: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: Spain: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: Spain: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: Russia: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: Russia: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Others: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Others: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Latin America: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Latin America: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Brazil: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Brazil: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: Mexico: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: Mexico: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 72: Others: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 73: Others: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 74: Middle East and Africa: Albumin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 75: Middle East and Africa: Albumin Market: Breakup by Country (in %), 2023
- Figure 76: Middle East and Africa: Albumin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Global: Albumin Industry: SWOT Analysis
- Figure 78: Global: Albumin Industry: Value Chain Analysis
- Figure 79: Global: Albumin Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Albumin Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Albumin Market Forecast: Breakup by Product (in Million US$), 2024-2032
- Table 3: Global: Albumin Market Forecast: Breakup by Application (in Million US$), 2024-2032
- Table 4: Global: Albumin Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 5: Global: Albumin Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 6: Global: Albumin Market: Competitive Structure
- Table 7: Global: Albumin Market: Key Players
Abstract
The global albumin market size reached US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The widespread product adoption in the operations to treat hypovolemia, the improving healthcare infrastructure, especially across developing regions, and the influx of both private and public investment in healthcare are some of the major factors propelling the market.
Albumin is a protein produced primarily by the liver and plays a vital role in various physiological functions. It is the most abundant protein in human blood plasma and serves to regulate blood volume by maintaining the osmotic pressure. Albumin also acts as a carrier molecule for substances such as hormones, fatty acids, and medications, aiding in their transport throughout the body. A key function of albumin is to help prevent fluid leakage from blood vessels, thus ensuring that essential fluids remain within the circulatory system. Abnormal levels of albumin in the blood can be indicative of various health conditions. Low levels may point to liver or kidney disorders, malnutrition, or chronic illness, while elevated levels are generally less common and could be indicative of dehydration or severe infection. Hence, the measurement of albumin levels is often included in blood tests as part of routine medical assessments.
The increasing number of surgical procedures majorly drives the global market. Albumin is commonly used in operations to treat hypovolemia, a condition where there is a decrease in the volume of blood plasma. As the global population continues to age and as surgical techniques continue to advance, the number of surgeries being performed is increasing. This trend directly correlates with an uptick in the demand for albumin, thereby driving market growth. Another significant factor contributing to market growth is the expansion of the albumin industry into emerging markets. Developing countries present an untapped market with increasing healthcare spending and improving healthcare infrastructure. As healthcare systems in these countries advance, the demand for high-quality medical supplies, including albumin, rises. In addition, the accelerating awareness about the importance of early diagnosis and treatment of conditions that require albumin is another factor driving the market. Moreover, the influx of both private and public investment in healthcare is creating a positive market outlook.
Albumin Market Trends/Drivers:
Rising Incidence of Chronic Diseases
One of the most significant market drivers for the albumin industry is the rising incidence of chronic diseases such as liver cirrhosis, kidney disorders, and diabetes. These conditions often result in abnormal albumin levels, necessitating regular monitoring and possible supplementation. In addition, the escalating prevalence of these chronic diseases is linked to an aging population, poor dietary habits, and lifestyle factors like lack of exercise and high stress levels. In confluence with this, the growing patient pool demands an increasing supply of albumin products for both diagnostic and therapeutic purposes. The escalating need for albumin in treating these diseases is thereby propelling growth in the industry. Hospitals and clinics are intensifying their reliance on albumin-based tests and treatments, thereby increasing demand and driving market growth.
Advances in Biotechnology and Pharmaceutical Research
Technological advancements in biotechnology and pharmaceutical research have also proven to be a major driver for the albumin industry. These advances have facilitated improved methods of isolating, purifying, and producing albumin on a large scale, thereby making it more accessible and cost-effective. Additionally, innovative techniques in recombinant DNA technology have opened new avenues for albumin applications, including its use as a drug delivery agent for targeted therapies. Additionally, progress in research has paved the way for albumin's use in novel applications such as wound healing and tissue regeneration. The ongoing investments in research and development activities indicate a promising trajectory for the albumin industry, contributing to its expansion.
Regulatory Support and Approvals
Governmental regulations and guidelines play a crucial role in driving the albumin market. Regulatory bodies provide guidelines for the safe production, quality control, and distribution of albumin products. In confluence with this, the presence of such standardizations not only builds consumer trust but also encourages pharmaceutical companies to invest in high-quality products. Timely approvals for new albumin-based products or therapies can substantially accelerate market penetration, thereby acting as a driver for the industry. Moreover, the global harmonization of these guidelines ensures a streamlined and efficient supply chain, facilitating faster time-to-market for new and innovative albumin-based products.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global albumin market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin
Human serum albumin dominates the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes human serum albumin, bovine serum albumin, and recombinant albumin. According to the report, human serum albumin represented the largest segment.
The market for human serum albumin products within the albumin industry is experiencing robust growth, propelled by multiple market drivers. A key influencer is the escalating prevalence of chronic liver and kidney diseases that necessitate regular monitoring and treatment of albumin levels. The rising number of surgical procedures, where human serum albumin is used to manage fluid balance, further fuels demand. Advances in biotechnological methods have made it easier to produce and purify human serum albumin, thereby making the product more cost-effective and accessible. This has led to its increased utilization in a range of medical and non-medical applications, such as drug formulation and vaccine stabilization. Additionally, the industry benefits from the regulatory support of agencies like the FDA and EMA, which ensures the quality and safety of these products, building consumer trust. Investment in healthcare from both public and private sectors also aids in market expansion, supporting research and development activities for innovative applications of human serum albumin. These factors collectively serve to drive the market for human serum albumin products.
Breakup by Application:
Therapeutics
Drug Formulation and Vaccine
Component of Media
Others
Therapeutics holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. These include therapeutics, drug formulation and vaccine, component of media, and others. According to the report, therapeutics accounted for the largest market share.
The therapeutics application segment in the albumin industry is witnessing significant growth, driven by multiple converging factors. Foremost among these is the increasing prevalence of chronic conditions like liver disease, kidney disorders, and diabetes, which necessitate the use of albumin-based treatments to regulate blood volume and protein levels. The rising number of surgical procedures, especially in an aging global population, also contributes to elevated demand for albumin as it is commonly used to manage fluid balance during surgeries. Advances in biotechnological research have led to the development of specialized albumin formulations optimized for drug delivery systems, thereby expanding its therapeutic applications. Regulatory bodies like the FDA and EMA have facilitated market growth by setting stringent quality control measures, thereby ensuring the efficacy and safety of albumin products used in therapeutics. Investments from private and public sectors in healthcare infrastructure and research also provide a conducive environment for the expansion of albumin's therapeutic applications. These driving factors combine to propel the market growth of the therapeutics application in the albumin industry.
Breakup by End User:
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Research Institutes
Hospitals and clinics dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes. According to the report, hospitals and clinics represented the largest segment.
The hospital and clinics segment is a major end-user in the albumin industry, and its market growth is fueled by several influential drivers. First and foremost, the rise in the incidence of chronic diseases like liver and kidney disorders requires consistent monitoring and treatment, often involving albumin-based products. This creates a steady demand for albumin in hospital settings for both diagnostic and therapeutic applications. Furthermore, the increasing number of surgical procedures that utilize albumin for fluid management further escalates demand within hospitals and clinics. Advances in healthcare infrastructure, supported by both public and private investment, have led to an uptick in the adoption of albumin products, as these settings aim for better patient outcomes and quality of care. Regulatory support, in the form of guidelines from bodies like the FDA and EMA, assures the quality of albumin products, thereby building trust and facilitating their usage in hospital settings. Collectively, these factors make hospitals and clinics a pivotal end-user segment, driving demand and, consequently, market growth for the albumin industry.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest albumin market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest segment.
The albumin industry in North America is experiencing significant growth, driven by a variety of factors that create a strong demand for albumin products. One major driver is the high prevalence of chronic conditions like liver diseases, kidney disorders, and diabetes in the region, necessitating frequent monitoring and intervention involving albumin. Additionally, North America has a well-developed healthcare infrastructure with a substantial number of surgical procedures taking place annually, thereby increasing the usage of albumin for surgical and critical care. Technological advancements in biopharmaceuticals, supported by considerable R&D investment, have also contributed to diversifying albumin applications, further driving the market. Regulatory support from agencies such as the FDA assures product quality and safety, enhancing consumer trust. Furthermore, public and private investments in healthcare have been strong, resulting in more hospitals, clinics, and healthcare facilities that use albumin products. These factors, along with a generally aging population that requires more healthcare services, collectively serve to propel the market growth for the albumin industry in North America.
Competitive Landscape:
The global market is experiencing significant growth due to the new albumin formulations and applications. Innovation in this area can lead to more effective and versatile albumin products, opening new markets and therapeutic avenues. Along with this, companies are expanding into emerging markets where there is rising healthcare spending and an increasing patient pool. This diversification helps mitigate risks associated with dependence on mature markets. In addition, the escalating strategic partnerships with other healthcare companies, research institutions, and even governmental bodies help in sharing knowledge, costs, and distribution networks. Therefore, this is significantly supporting the market. With regulatory bodies emphasizing the safety and efficacy of medical products, companies in the albumin market are focusing on quality control to adhere to these guidelines, further impacting the market. In addition, brands are adopting advanced logistics and inventory management systems to ensure timely delivery, which is acting as another growth-inducing factor. Furthermore, product differentiation by offering albumin products that serve specific niches within healthcare is contributing to the market.
The market report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Albumedix Ltd.
Biotest AG
Celgene Corporation (Bristol-Myers Squibb Company)
CSL Limited
Grifols SA
HiMedia Laboratories
Medxbio Pte Ltd.
Merck KGaA
Octapharma AG
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Ventria Bioscience Inc.
Recent Developments:
In July 2023, Grifols SA finished enrolling participants in its Phase III PRECIOSA clinical study using long-term Albutein (albumin-human injectable) treatment to prolong life in patients with decompensated cirrhosis.
In June 2023, Albumedix Ltd announced the extension of its current partnership with Valneva SE, a specialized vaccination business devoted to the prevention of infectious illnesses with important unmet medical needs.
In October 2022, Biotest AG announced the signing of a Memorandum of Understanding with Biotest AG for the production of plasma derivatives under a private label by Alpha Pharma for the KSA market.
Key Questions Answered in This Report
- 1. What was the size of the global albumin market in 2023?
- 2. What is the expected growth rate of the global albumin market during 2024-2032?
- 3. What are the key factors driving the global albumin market?
- 4. What has been the impact of COVID-19 on the global albumin market?
- 5. What is the breakup of the global albumin market based on the product?
- 6. What is the breakup of the global albumin market based on the application?
- 7. What is the breakup of the global albumin market based on end user?
- 8. What are the key regions in the global albumin market?
- 9. Who are the key players/companies in the global albumin market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Albumin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Human Serum Albumin
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bovine Serum Albumin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Recombinant Albumin
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Application
- 7.1 Therapeutics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Drug Formulation and Vaccine
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Component of Media
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Pharmaceutical and Biotechnology Companies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Albumedix Ltd
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Biotest AG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Celgene Corporation (Bristol-Myers Squibb Company)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 SWOT Analysis
- 14.3.4 CSL Limited
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Grifols SA
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 HiMedia Laboratories
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Medxbio Pte Ltd
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Merck KGaA
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Octapharma AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 SWOT Analysis
- 14.3.10 Takeda Pharmaceutical Company Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Thermo Fisher Scientific Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Ventria Bioscience Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.1 Albumedix Ltd
